Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really depends on how positive the publication is. I’m not sure how much profit taking is going to happen. Seems like there are quite a few shareholders that want to see this one through to approval and beyond.
Were not going anywhere too fast from here. But I like what Ike has been saying. This isn’t going to go anywhere fast. We’re probably going to see more dilution to get to the end, but I think the more positive the publication is, the less dilution we’ll need. Warrant money is key to getting us across the finish line and the shorts are trying to starve us of it. But expiring warrants act to consolidate the effect of dilution. That’s why I laugh at AF’s bulls$-t. He keeps painting a picture of billions of shares when warrants have been expiring worthless and have had a minor consolidating effect. That is never mentioned.
I believe in the science and am ready to let my investment here simmer. I don’t day trade and look forward to seeing this back at $2-$5 in the next few years.
I agree. We rally next week into the pub. Depending on what the blinded pub says, this could really keep rallying.
Maybe Less is Dilly Dillying in the pit of misery after yesterday’s bounce?
Not likely. Probably not a ton of short action on this one at .17. The smart shorts have already made their money here. Bankruptcy is off the table for now. Blinded publication will determine our path forward.
They reiterated guidance of 6-9 months for publication from October/November submit date. So I’d expect publication anytime now. They concurred that publication process was frustratingly slow. I’m ok with that, as long as they get it right.
Buy now while the getting is still good. Anything under .25 is a steal. The next three years are going to be quite a run here.
So from the meeting, it appears that this one is going to be on simmer for a while. They’ll give long term shareholders more opportunity to average down, but they seem very intent on waiting for analysis. I’m with Ike...no urgent need for my NWBO money. Nobody is really going to get rich from a mega short play here, so we’re probably close to bottom. There may be a bit more dilution, but they’ll probably sell preferreds to supportive investors to raise funds until approval. As positive data mounts, there probably will be incremental gains until approval. At which point (maybe late 2019?) we could be sitting on 1.1 billion common shares and a 2-5 billion market cap?
I think this was SoS call in January. The strong sentiment here is that we have a winner. Management seems to feel good, and they’ve seen the pending paper. I’ll just hold until the science confirms it.
I was hoping for a get rich quicker scheme, but I’ll balance management’s confidence in the product with their communication of a more extended timeline.
Thank you Ike!
Rumor has it that the meeting was “very positive”. I think price is reflecting that.
Another good question for Linda is if she considers the 8-k disclosed 4.4 million a loan or a purchase of company securities.
Yup...clearly, the next big thing is right on our tail.
Yup. We started P3 in 2008? Theyre right on our tail.
Probably why Linda Liau has no financial interest in NWBO. It makes her research completely independent of the financial considerations.
I’ve mastered the obvious
The Optune trial was also not blinded. Preferential selective criteria for patients were also included, mainly, those who can tolerate a large medical device to their head.
May not be apples to apples here...
I’m a bit bewildered. But I recognize that there is no exact schedule to publish a paper. Management has been speculating incorrectly about timelines for years.
Maybe they should predict a paper in 2019. Then it would be released next week.
Those institutions don’t have the funding to sponsor and conduct three phase clinical trials. You don’t seem to understand how the clinical trial system works...
Couldn’t say it better myself. This trial will change cancer therapy.
Weak hands.
I’d bet there are somewhere between 65-95 patients still alive in the trial. Of the 100 that we’re alive last spring, I’d expect a continued slowing rate of eventing.
The next few months are going to be fun here. This stock isn’t a fraud, it’s about science. And there is no predictable timeline on a new therapy like this. While the company may fail due to poor management, I am convinced that the trial will not. The real question is, what is a working advancement in the fight against GBM worth?
Pseudoprogression will probably make PFS a mess.
We can all dream. I think they’ve met the end point on mOS. PFS could be indeterminate and part of the cause of the delays.
If it proves successful and gets to 0.85, it will probably generate another 50 million in warrant money, which should get us to commercialization. That’s what the shorts are really afraid of here and that could cause a squeeze.
If they can prove they have a successful product here... at least 3-4 month mOS greater than Stupp trial, then the price should jump to the point that warrant money can be accessed. Most of the company’s liabilities are in outstanding warrants.
Success will bring in buyout offers. That is the best hope at this point. I’m pretty sure that NWBO doesn’t have the cash or the ability to dilute and go it alone from here. But they could draw BP into a bidding war with a successful trial.
He’s a good guy. I have lunch with him every now and then. He won’t mind the confusion. I think we’re all a little confused on this board.
I’m a big fan of the Alpha Puppy’s work. He’s a smart researcher.
Tomorrow is the day. ASCO abstracts should give insight into whether the company has intentions to show the world something at ASCO. We got some good information last year. This year is hopefully our year.
I agree that Cofer would walk if this stunk. He walked when he found out there were illegal payments to Iraqi officials in the security operation he ran. He must have integrity.
Let’s imagine that there is an investigation going on surrounding this security. Not an investigation of management, but of external forces. I mean, if management had something to hide, why would they bring in the ex CIA director of counter terrorism to sit on the board of directors? Somebody who is very well connected to government law enforcement to help hide their cover up? Not likely. Cofer spent his career taking down forces of evil. Now he’s joining an entity trying to cover up a massive fraud? Not likely.
A likelier scenario is that there could be an investigation going on behind the scenes. An investigation that demands silence. Whether something criminal is proven remains to be determined.
His intentions are pretty clear. Who his voice represents is not. SEC could be looking into that...
You may be right. They may be total liars. But like I said, if they are lying, they really suck at that too.
We were told at the ASM that a publication had been submitted with 65 co-authors. Do you think that was make believe? Do you know what happens to a publication that has been submitted by 65 co-authors? It is reviewed by peers (in this case, doctors and scientists) to ensure the validity of the data being published. Unless this company is now a fictitious entity and is making up information about their P3 trial and data, I believe that what they have stated is true. I mean, if they were going to make stuff up out of thin air, they should make up that 80% of GBM patients treated in the trial are still alive. They could also make up that DCVax has also been found to cure male pattern baldness, erectile dysfunction, and reduces unwanted fat on patients by an average of 30 lbs. All with no side effects.
Just saying that if they are lying, they really suck at that too.
I always say...they didn’t build Vegas with the money that they’ve been giving away to tourists all these years.
It was revealed in September and it was reiterated at the ASM in January. You really think management is making data and publication information up? That’s a wild conspiracy theory.
We know where the process stands. There are a bunch of doctors and scientists reviewing the paper on the P3 blinded data that was submitted for publication. If that isn’t happening, we can expect some serious lawsuits in the future. With data like that contains huge ramifications like this, I’d imagine there is serious scrutiny being poured into the process.
Ouch...That’s gonna be hard to make back. I’m down, but my cost average is around .25. No reason to sell here.
I’m hoping you make everything back! I’m hoping this vaccine gets approved for the 1/4 of patients that it could cure. I’m hoping that it leads to more research as to how to push those cure rates to 50% and beyond.
GLTY
You don’t lose until you sell or are forced to sell.
You’re right. Short it down. Print shares to short. Wall St. is counting on more lots more dilution or bankruptcy to cover those.
BUT...if that data gets out and it’s undeniably good, watch out.
Don’t think for a moment that the forces in play here aren’t lobbying lawmakers or bribing scientists. Fighting dirty pays the bills when big money is on the line.
Lucky dude.
Looks like the smart money is speaking today.